We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
Read MoreHide Full Article
Glaukos Corporation (GKOS - Free Report) announced that the FDA has approved its iDose TR (travoprost intracameral implant). The approval is for slow-release 75mcg iDose TR for the reduction of intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
The approval is based on data from a phase III program consisting of two pivotal studies that evaluated the safety and efficacy of a single administration of one of two iDose TR models with different travoprost release ratesin reducing IOP in subjects with open-angle glaucoma or ocular hypertension.
This revolutionary, micro-invasive injectable treatment marks a new era in interventional glaucoma therapy.
Price Performance
Share of Glaukos have risen more than 30% following the FDA approval. The company’s shares have risen 81% year to date compared with the industry’s 1.7% growth. The S&P 500 Index has increased 23.4% in the same time frame.
Image Source: Zacks Investment Research
Strategic Advantages: A New Era in Interventional Glaucoma
iDose TR is designed for a single administration per eye, sets itself apart as a long-duration, intracameral procedural pharmaceutical therapy. By delivering continuous therapeutic levels of travoprost, it addresses the challenges of patient non-compliance and chronic side effects associated with conventional topical glaucoma medications. This approval positions Glaukos as a frontrunner in redefining the standard of care for glaucoma patients.
Data from the pivotal studies demonstrated that a remarkable 81% of iDose TR subjects were free of IOP-lowering topical medications at 12 months. The clinical studies showcased excellent tolerability and subject retention, positioning iDose TR as a potential solution to the challenges posed by traditional glaucoma treatments.
Commercial Outlook
Glaukos plans to initiate commercial activities for iDose TR in the latter part of the first quarter of 2024. With a wholesale acquisition cost of $13,950 per dose, the company aims to bring this innovative therapy to the forefront of interventional glaucoma treatment.
GKOS’ reaffirmation of 2023 net sales projection and introduction of preliminary 2024 net sales guidance, ranging between $350 million and $360 million, underscore the confidence in iDose TR's potential to contribute significantly to Glaukos' growth in the coming years.
ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%. The company’s shares have risen 42.5% year to date compared with the industry’s 1.7% growth.
HealthEquity, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 26.8%. HQY’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 16.5%.
The company’s shares have rallied 15% year to date against the industry’s 9.9% decline.
Biodesix, carrying a Zacks Rank #2 at present, has an estimated growth rate of 32.3% for 2024. BDSX’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.76%.
The stock has fallen 30.9% year to date compared with the industry’s 9.9% decline.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
Glaukos Corporation (GKOS - Free Report) announced that the FDA has approved its iDose TR (travoprost intracameral implant). The approval is for slow-release 75mcg iDose TR for the reduction of intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
The approval is based on data from a phase III program consisting of two pivotal studies that evaluated the safety and efficacy of a single administration of one of two iDose TR models with different travoprost release ratesin reducing IOP in subjects with open-angle glaucoma or ocular hypertension.
This revolutionary, micro-invasive injectable treatment marks a new era in interventional glaucoma therapy.
Price Performance
Share of Glaukos have risen more than 30% following the FDA approval. The company’s shares have risen 81% year to date compared with the industry’s 1.7% growth. The S&P 500 Index has increased 23.4% in the same time frame.
Image Source: Zacks Investment Research
Strategic Advantages: A New Era in Interventional Glaucoma
iDose TR is designed for a single administration per eye, sets itself apart as a long-duration, intracameral procedural pharmaceutical therapy. By delivering continuous therapeutic levels of travoprost, it addresses the challenges of patient non-compliance and chronic side effects associated with conventional topical glaucoma medications. This approval positions Glaukos as a frontrunner in redefining the standard of care for glaucoma patients.
Data from the pivotal studies demonstrated that a remarkable 81% of iDose TR subjects were free of IOP-lowering topical medications at 12 months. The clinical studies showcased excellent tolerability and subject retention, positioning iDose TR as a potential solution to the challenges posed by traditional glaucoma treatments.
Commercial Outlook
Glaukos plans to initiate commercial activities for iDose TR in the latter part of the first quarter of 2024. With a wholesale acquisition cost of $13,950 per dose, the company aims to bring this innovative therapy to the forefront of interventional glaucoma treatment.
GKOS’ reaffirmation of 2023 net sales projection and introduction of preliminary 2024 net sales guidance, ranging between $350 million and $360 million, underscore the confidence in iDose TR's potential to contribute significantly to Glaukos' growth in the coming years.
Glaukos Corporation Price
Glaukos Corporation price | Glaukos Corporation Quote
Zacks Rank & Stocks to Consider
Glaukos currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Integer Holdings (ITGR - Free Report) , HealthEquity, Inc. (HQY - Free Report) and Biodesix (BDSX - Free Report) .
Integer Holdings, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 33.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%. The company’s shares have risen 42.5% year to date compared with the industry’s 1.7% growth.
HealthEquity, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 26.8%. HQY’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 16.5%.
The company’s shares have rallied 15% year to date against the industry’s 9.9% decline.
Biodesix, carrying a Zacks Rank #2 at present, has an estimated growth rate of 32.3% for 2024. BDSX’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.76%.
The stock has fallen 30.9% year to date compared with the industry’s 9.9% decline.